Combination Of Antigens From Multiple Viral Species (e.g., Multivalent Viral Vaccine, Etc.) Patents (Class 424/202.1)
  • Patent number: 10175236
    Abstract: The present invention discloses an in vitro method for diagnosing a Leptospira infection in a biological sample of a subject, comprising a step of contacting said sample with bacterial cells of a serovar of the Leptospira fainei species, preferably bacterial cells of the Leptospira fainei serovar Hurstbridge, or an antigenic fraction of said bacterial cells. In a preferred embodiment, said Leptospira infection is not due to bacteria belonging to the serovar of the Leptospira fainei species used in the diagnostic method.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 8, 2019
    Assignee: Institut Pasteur
    Inventors: Pascale Bourhy, Suzanne Chanteau, Cyrille Goarant, Mathieu Picardeau, Faradibano Nato, Sylvie Dartevelle
  • Patent number: 10160957
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 25, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Patent number: 10155031
    Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: December 18, 2018
    Assignees: BioNTech RNA Pharmaceuticals GmbH, TRON (Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbH
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
  • Patent number: 10080793
    Abstract: The present invention relates to a method for prevention and/or reduction of aggregation of viral components.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 25, 2018
    Assignee: De Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en Sport
    Inventors: Arend Gesinus van't Oever, Wilfridus Adrianus Maria Bakker, Yvonne Elisabeth Thomassen
  • Patent number: 10071199
    Abstract: Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: September 11, 2018
    Assignee: InCube Labs, LLC
    Inventor: Mir Imran
  • Patent number: 9919025
    Abstract: Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: March 20, 2018
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Patent number: 9889187
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: February 13, 2018
    Assignees: Virginia Tech Intellectual Properties, Inc., Iowa State University Foundation, Inc.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Patent number: 9783787
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: October 10, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Patent number: 9731020
    Abstract: The present invention relates to formulations and methods for stabilizing and protecting of biologic materials during harsh storing and use conditions, wherein the formulations relate to embedded bioactive materials and biologics, including live bacteria, in a protective glassy matrix.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: August 15, 2017
    Assignee: Advanced Bionutrition Corp.
    Inventors: Moti Harel, Roger Drewes, January Scarbrough
  • Patent number: 9718875
    Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 1, 2017
    Assignee: ContraFect Corporation
    Inventors: Michael Wittekind, Adam Vigil
  • Patent number: 9526778
    Abstract: The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: December 27, 2016
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale, National University of Singapore
    Inventors: Sylvie Alonso, Rui Li, Vincent Chow, Camille Locht
  • Patent number: 9476878
    Abstract: The present invention relates to a method for polypeptide transfer into cells. The present invention further relates to the detection of polypeptide-specific immune cells and the priming, expansion and reactivation of polypeptide-specific T cells. Moreover the present invention relates to polypeptides of the methods of the present invention in combination with urea and their use for research, diagnosis or treatment and prevention of diseases in animals and humans.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 25, 2016
    Assignee: LOPHIUS BIOSCIENCES GMBH
    Inventors: Sascha Barabas, Katrin Edmaier, Ludwig Deml
  • Patent number: 9364527
    Abstract: Methods for stimulating immune responses in a bovine animal susceptible to infection by Leptospira hardjo-bovis are disclosed. In the methods, a composition of inactivated L. hardjo-bovis and an adjuvant is administered to the animal within about 4 weeks of birth. The immune responses stimulated in the animal prevent or shorten the duration of a subsequent L. hardjo-bovis infection. The immune response is effective for at least a year.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: June 14, 2016
    Assignee: NOVARTIS TIERGESUNDHEIT AG
    Inventor: Eric Springer
  • Patent number: 9364530
    Abstract: The present invention relates to novel virus-like particles (VLPs) comprising a matrix protein derived from a first plant enveloped virus and a surface polypeptide. The surface polypeptide comprises (a) a surface exposed portion derived from a target polypeptide (b) a transmembrane domain, and (c) a cytosolic tail derived from a transmembrane (e.g., glycoprotein) of a second plant enveloped virus. The target polypeptide may be antigenic or therapeutic. The first and the second plant enveloped viruses may be the same. Either plant enveloped virus may be a plant rhabdovirus. Also provided are methods of making and using the VLPs.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 14, 2016
    Assignee: Fraunhofer USA, Inc.
    Inventors: Alexei Prokhnevsky, Vidadi Yusibov
  • Patent number: 9314519
    Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: April 19, 2016
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Kevin O'Connell
  • Patent number: 9303070
    Abstract: The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: April 5, 2016
    Assignee: BiondVax Pharmaceuticals Ltd.
    Inventors: Tamar Ben-Yedidia, George H. Lowell
  • Patent number: 9211324
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: December 15, 2015
    Assignees: Virginia Tech Intellectual Properties, Inc., Iowa State University Research Foundation, Inc.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Patent number: 9011874
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 21, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
  • Patent number: 9011873
    Abstract: The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Duke University, Beth Israel Deaconess Medical Center, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
  • Patent number: 9005632
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: April 14, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
  • Publication number: 20150098965
    Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 9, 2015
    Inventor: JANET K. YAMAMOTO
  • Publication number: 20150079077
    Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).
    Type: Application
    Filed: January 25, 2013
    Publication date: March 19, 2015
    Inventors: Marc J. Kirchmeier, David E. Anderson
  • Patent number: 8968996
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Grant
    Filed: June 10, 2012
    Date of Patent: March 3, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Publication number: 20150056247
    Abstract: The present invention provides a combined AIDS vaccine for preventing and/or treating AIDS, which consists of four or more different vector-based AIDS vaccines, wherein HIV protein gene comprised in the different AIDS vaccines may be same.
    Type: Application
    Filed: December 23, 2011
    Publication date: February 26, 2015
    Applicants: NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND, BEIJING UNIVERSITY OF TECHNOLOGY
    Inventors: Yi Zeng, Xia Feng, Shuangqing Yu, Ling Yang, Zelin Li, Wei Kong, Xianghui Yu
  • Patent number: 8961991
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: February 24, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Publication number: 20150050305
    Abstract: Immunogenic compositions directed against Hendra and/or Nipah viruses, and methods of its use, are provided. In addition, methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and/or Nipah virus are provided.
    Type: Application
    Filed: May 14, 2012
    Publication date: February 19, 2015
    Applicant: ZOETIS LLC
    Inventors: Martin Elhay, Christopher C. Broder, Jin-an Huang
  • Patent number: 8956626
    Abstract: Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 17, 2015
    Assignees: Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Vincent Moules, Manuel Rosa-Calatrava, Olivier Ferraris, Matthieu Yver
  • Patent number: 8956625
    Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Patent number: 8945584
    Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 3, 2015
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
  • Patent number: 8889146
    Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Ventzislav B. Vassilev, Virginie Van Scherpenzeel Thim, Normand Blais, Patrick Rheault
  • Patent number: 8883169
    Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
  • Publication number: 20140322267
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Gregory HAIWICK, Luis HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Patent number: 8871222
    Abstract: The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: October 28, 2014
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Konstantin V. Pugachev, Farshad Guirakhoo, Thomas P. Monath
  • Publication number: 20140314806
    Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Inventors: Michelle Allen, Mark Garrett, Urs Peter Bruderer, Martinus Antonius Johannes Thijssen
  • Patent number: 8846054
    Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Carol L. Rinehart, Craig Jones, Judy Myers-Kuhnhoff, Wayne Cole, William Charles Ohnesorge
  • Publication number: 20140287043
    Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
    Type: Application
    Filed: April 23, 2012
    Publication date: September 25, 2014
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo Omenetto
  • Patent number: 8821889
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Patent number: 8821885
    Abstract: The invention is directed to immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: September 2, 2014
    Assignee: Longhorn Vaccines & Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Publication number: 20140220073
    Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: SANOFI PASTEUR SA
    Inventors: Alain BOUCKENOOGHE, Remi FORRAT, Denis CREVAT
  • Publication number: 20140219954
    Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.
    Type: Application
    Filed: March 17, 2014
    Publication date: August 7, 2014
    Inventor: Rudi Mueller-Walz
  • Patent number: 8790657
    Abstract: This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: July 29, 2014
    Assignee: Biomune Company
    Inventors: Kristi Mae Dorsey, John Knox Rosenberger, Sandra Cloud Rosenberger
  • Patent number: 8778355
    Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: July 15, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Knut Elbers, Christiane Fetzer, Martina von Freyburg, Gregor Meyers
  • Patent number: 8771704
    Abstract: The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions with endothelial cells and platelets, and is able to shorten the bleeding time.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: July 8, 2014
    Assignee: National Cheng Kung University
    Inventor: Yee-Shin Lin
  • Patent number: 8748127
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: June 10, 2014
    Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
  • Publication number: 20140154284
    Abstract: Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.
    Type: Application
    Filed: July 17, 2012
    Publication date: June 5, 2014
    Applicant: The United States of America,as represented by the Secretary Department of Health & Human Services
    Inventors: Christopher B. Buck, Diana V. Pastrana
  • Publication number: 20140154265
    Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.
    Type: Application
    Filed: September 24, 2013
    Publication date: June 5, 2014
    Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
  • Patent number: 8734808
    Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 27, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Publication number: 20140141040
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Publication number: 20140134202
    Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.
    Type: Application
    Filed: December 13, 2011
    Publication date: May 15, 2014
    Applicant: FOLIA BIOTECH INC.
    Inventors: Denis LECLERC, Nathalie MAJEAU, Constantino Roberto LOPEZ-MACIAS, III, Alain LAMARRE
  • Patent number: 8715689
    Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: May 6, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Claire Y. H. Kinney, Eric Thomas Beck, Richard M. Kinney